CN102812023A - 抗感染吡啶并(1,2-a)嘧啶类 - Google Patents

抗感染吡啶并(1,2-a)嘧啶类 Download PDF

Info

Publication number
CN102812023A
CN102812023A CN2011800059743A CN201180005974A CN102812023A CN 102812023 A CN102812023 A CN 102812023A CN 2011800059743 A CN2011800059743 A CN 2011800059743A CN 201180005974 A CN201180005974 A CN 201180005974A CN 102812023 A CN102812023 A CN 102812023A
Authority
CN
China
Prior art keywords
nmr
amino
alkyl
pyrido
400mhz
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN2011800059743A
Other languages
English (en)
Chinese (zh)
Inventor
卢载成
金在昇
P·布鲁丁
徐旻廷
朴垠铮
J·塞彻托
全希暻
A·吉诺维索
李世渊
姜善姬
F·A·伊万
南芝娟
D·P·C·芬尼斯泰恩
T·克里斯托佛
M·康特雷拉斯多名盖斯
金恩惠
许慈明
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
NATIONAL HEALTH AND MEDICINE INST
Institut National de la Sante et de la Recherche Medicale INSERM
Institut Pasteur Korea
Original Assignee
NATIONAL HEALTH AND MEDICINE INST
Institut Pasteur Korea
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by NATIONAL HEALTH AND MEDICINE INST, Institut Pasteur Korea filed Critical NATIONAL HEALTH AND MEDICINE INST
Publication of CN102812023A publication Critical patent/CN102812023A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
CN2011800059743A 2010-01-13 2011-01-13 抗感染吡啶并(1,2-a)嘧啶类 Pending CN102812023A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US29455210P 2010-01-13 2010-01-13
US61/294,552 2010-01-13
PCT/EP2011/000135 WO2011085990A1 (en) 2010-01-13 2011-01-13 Anti - infective pyrido (1,2 -a) pyrimidines

Publications (1)

Publication Number Publication Date
CN102812023A true CN102812023A (zh) 2012-12-05

Family

ID=43610218

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2011800059743A Pending CN102812023A (zh) 2010-01-13 2011-01-13 抗感染吡啶并(1,2-a)嘧啶类

Country Status (9)

Country Link
US (1) US20130012506A1 (pt-PT)
EP (1) EP2523956A1 (pt-PT)
JP (1) JP2013517233A (pt-PT)
KR (1) KR20130088002A (pt-PT)
CN (1) CN102812023A (pt-PT)
AU (1) AU2011206761A1 (pt-PT)
BR (1) BR112012017473A2 (pt-PT)
CA (1) CA2786329A1 (pt-PT)
WO (1) WO2011085990A1 (pt-PT)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105153151A (zh) * 2015-08-28 2015-12-16 张文莲 一种嘧啶酮类化合物的合成方法
CN107001360A (zh) * 2014-12-02 2017-08-01 普拉纳生物技术有限公司 4H‑吡啶并[1,2‑a]嘧啶‑4‑酮化合物

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX354074B (es) 2012-02-10 2018-02-12 Ptc Therapeutics Inc Compuestos para tratar la atrofia muscular espinal.
BR112014021531B1 (pt) 2012-03-01 2022-10-04 Ptc Therapeutics, Inc. Composto, composição farmacêutica e usos dos mesmos
US9914722B2 (en) 2012-03-23 2018-03-13 Ptc Therapeutics, Inc. Compounds for treating spinal muscular atrophy
EP3082820B1 (en) 2013-12-19 2022-07-20 PTC Therapeutics, Inc. Methods for modulating the amount of rna transcripts
WO2016196386A1 (en) 2015-05-30 2016-12-08 Ptc Therapeutics, Inc. Methods for modulating rna splicing
ES2879995T3 (es) 2015-12-10 2021-11-23 Ptc Therapeutics Inc Métodos para el tratamiento de la enfermedad de Huntington
US11702646B2 (en) 2016-11-28 2023-07-18 Ptc Therapeutics, Inc. Methods for modulating RNA splicing
EA201992878A1 (ru) 2017-06-05 2020-05-08 ПиТиСи ТЕРАПЬЮТИКС, ИНК. Соединения для лечения болезни хантингтона
CN111372611A (zh) 2017-06-14 2020-07-03 Ptc医疗公司 修饰rna剪接的方法
BR112019027717A2 (pt) 2017-06-28 2020-07-28 Ptc Therapeutics, Inc. métodos para tratar a doença de huntington
MX2019015580A (es) 2017-06-28 2020-07-28 Ptc Therapeutics Inc Metodos para tratar la enfermedad de huntington.
CN112135815A (zh) 2018-03-27 2020-12-25 Ptc医疗公司 用于治疗亨廷顿氏病的化合物
EP3814360A1 (en) 2018-06-27 2021-05-05 PTC Therapeutics, Inc. Heteroaryl compounds for treating huntington's disease
AU2019294478B2 (en) 2018-06-27 2023-03-23 Ptc Therapeutics, Inc. Heterocyclic and heteroaryl compounds for treating Huntington's disease
CN114106000B (zh) * 2021-12-15 2023-11-24 中国科学院新疆理化技术研究所 一种咪唑并[4,5-d]嘧啶酮三环类衍生物及抗肿瘤用途

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1422256A (zh) * 2000-02-09 2003-06-04 第一制药株式会社 包含作为活性成分的吡啶酮羧酸的抗耐酸细菌药
WO2010001366A1 (en) * 2008-07-04 2010-01-07 Institut National De La Sante Et De La Recherche Medicale (Inserm) Piperazines derivatives as proteasome modulators
CN102105470A (zh) * 2008-06-17 2011-06-22 韩国巴斯德研究所 作为抗结核病药的吡啶并嘧啶化合物

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4235871A (en) 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
US4501728A (en) 1983-01-06 1985-02-26 Technology Unlimited, Inc. Masking of liposomes from RES recognition
US4603044A (en) 1983-01-06 1986-07-29 Technology Unlimited, Inc. Hepatocyte Directed Vesicle delivery system
US5075109A (en) 1986-10-24 1991-12-24 Southern Research Institute Method of potentiating an immune response
US4837028A (en) 1986-12-24 1989-06-06 Liposome Technology, Inc. Liposomes with enhanced circulation time
US4897268A (en) 1987-08-03 1990-01-30 Southern Research Institute Drug delivery system and method of making the same
US4957773A (en) 1989-02-13 1990-09-18 Syracuse University Deposition of boron-containing films from decaborane
EP2219646A4 (en) * 2007-12-21 2010-12-22 Univ Rochester METHOD FOR MODIFYING THE LIFETIME OF EUKARYOTIC ORGANISMS

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1422256A (zh) * 2000-02-09 2003-06-04 第一制药株式会社 包含作为活性成分的吡啶酮羧酸的抗耐酸细菌药
CN102105470A (zh) * 2008-06-17 2011-06-22 韩国巴斯德研究所 作为抗结核病药的吡啶并嘧啶化合物
WO2010001366A1 (en) * 2008-07-04 2010-01-07 Institut National De La Sante Et De La Recherche Medicale (Inserm) Piperazines derivatives as proteasome modulators

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
CA: "REGISTRY COPYRIGHT", 《ACS ON STN》, 3 February 2009 (2009-02-03), pages 3 - 8 *
CARSTEN PLÜG ET AL: "Mesoionic pyridopyrimidinylium and pyridooxazinylium olates and non-mesoionic pyridopyrimidinones. Structures in the solid state, solution, and matrices", 《J. CHEM. SOC., PERKIN TRANS. 2》, 31 December 2000 (2000-12-31), pages 11 *
HEIDI GADE ANDERSEN ET AL: "Ketenes and mesoions. Interconversion of mesoionic pyridopyrimidinium olates and pyridopyrimidinones. (2-Pyridyl)iminopropadienone. Part 2", 《J. CHEM. SOC., PERKIN TRANS. 2》, 31 December 2001 (2001-12-31), pages 7 *

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107001360A (zh) * 2014-12-02 2017-08-01 普拉纳生物技术有限公司 4H‑吡啶并[1,2‑a]嘧啶‑4‑酮化合物
CN107001360B (zh) * 2014-12-02 2020-09-18 普拉纳生物技术有限公司 4H-吡啶并[1,2-a]嘧啶-4-酮化合物
CN111961050A (zh) * 2014-12-02 2020-11-20 普拉纳生物技术有限公司 4H-吡啶并[1,2-a]嘧啶-4-酮化合物
CN105153151A (zh) * 2015-08-28 2015-12-16 张文莲 一种嘧啶酮类化合物的合成方法

Also Published As

Publication number Publication date
KR20130088002A (ko) 2013-08-07
AU2011206761A2 (en) 2012-12-13
WO2011085990A1 (en) 2011-07-21
EP2523956A1 (en) 2012-11-21
JP2013517233A (ja) 2013-05-16
CA2786329A1 (en) 2011-07-21
AU2011206761A1 (en) 2012-07-12
WO2011085990A8 (en) 2012-10-26
US20130012506A1 (en) 2013-01-10
BR112012017473A2 (pt) 2019-09-24

Similar Documents

Publication Publication Date Title
CN102812023A (zh) 抗感染吡啶并(1,2-a)嘧啶类
KR101574332B1 (ko) 항감염성 화합물
US20100317607A1 (en) Use of compounds for preparing anti-tuberculosis agents
US20090156578A1 (en) 3-Heterocyclylacrylamide Compounds as Fab I Inhibitors and Antibacterial Agents
WO2013033981A1 (zh) 一类2,7-萘啶衍生物及其制备方法和应用
TWI601724B (zh) 咪唑並喹啉類衍生物及其可藥用鹽、其製備方法及其在醫藥上的應用
EP2675791B1 (en) Substituted 6,7-dialkoxy-3-isoquinolinol derivatives as inhibitors of phosphodiesterase 10 (pde10a)
WO2007053131A2 (en) Acrylamide derivatives as antibiotic agents
CN106795152B (zh) 蛋白激酶抑制剂
JP2006517976A (ja) 新規化合物
CA3204171A1 (en) Bicyclic derivatives
KR20110016947A (ko) 트리시클릭 질소 함유 화합물 및 항박테리아제로서의 그의 용도
WO2019080723A1 (zh) 多取代吡啶酮类衍生物、其制备方法及其医药用途
Coulibaly et al. Phenanthrolinic analogs of quinolones show antibacterial activity against M. tuberculosis
CN110997651B (zh) 新的四唑化合物和它们在治疗结核病中的用途
RU2800930C2 (ru) Новые производные тетразола и их применение в лечении туберкулеза

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20121205